Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. - Wikidata - awgldk - TriplyDB

Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.

Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.

http://www.wikidata.org/entity/Q37373261

about

Is elimination of hepatitis C from the UK by 2030 a realistic goal?Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C.

P2860

Q38729888-3C2A356D-BE94-4D7B-88A0-B776786AE2BC Q41921724-427182AB-65B6-4758-94C7-601821C4A46E Q47397635-3C62DFB6-46CC-4AD7-BC29-127C7B705CCD

P2860

Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.

http://www.wikidata.org/entity/Q37373261

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Polymorphisms and resistance m ...... an hepatitis C virus database.

@en

Polymorphisms and resistance m ...... an hepatitis C virus database.

@nl

type

label

Polymorphisms and resistance m ...... an hepatitis C virus database.

@en

Polymorphisms and resistance m ...... an hepatitis C virus database.

@nl

prefLabel

Polymorphisms and resistance m ...... an hepatitis C virus database.

@en

Polymorphisms and resistance m ...... an hepatitis C virus database.

@nl

P1433

Q37373261-AF6254C4-BB81-46AE-8F32-42414960E34E

P1476

Q37373261-8D6DF9DD-373E-488B-88D6-C8AD62CB2089

P2093

Q37373261-0911B36E-847E-4867-85FD-048FAADD885B

Q37373261-186D6FD8-9A39-486E-A5C1-6FC6861DEE5A

Q37373261-EDEB6282-4072-4D14-B2B0-8AFE605F51E4

Q37373261-FE6E3C83-1AE6-4E4F-9526-7317CCA81A10

P2860

Q37373261-0C989DEA-F998-436D-BA6C-EC4D2685F0F3

Q37373261-109CA128-1D7D-40D6-9BD0-E563ADC3F0AE

Q37373261-135E2043-13C2-4921-85CA-127885C56DF5

Q37373261-3777D59B-DED9-443D-A2E2-B74D4C34CAD6

Q37373261-3CFB8C27-C30C-4A90-AFDD-778E3008A603

Q37373261-436E527D-AB00-44BF-8BEB-5A454572E369

Q37373261-49C8C41F-CE22-4B9A-9F5A-53DA5902E891

Q37373261-4B15A52C-E403-4141-B227-6CBCBF4C1824

Q37373261-52FED780-CB5C-4A5C-9D69-BE55813AB76A

Q37373261-535041E6-1702-4F6E-AB1A-57473B12EE79

P304

Q37373261-5F3CE5D3-BBFB-4864-AF47-AA911E4F75A7

P31

Q37373261-2C051A19-E136-4BFA-8256-96E57EDE3218

P356

Q37373261-F8BA9FAA-5F22-4681-A8D1-D23896854876

P407

Q37373261-F7DFE1FE-5212-493C-9720-3971915A7468

P433

Q37373261-19A9B882-CF53-4CDB-A241-17EC93A61B6B

P478

Q37373261-B5763A75-E067-4140-98FC-B19AEB14E0D8

P50

Q37373261-5437970F-2C95-40D7-99B6-5558B1A05415

P577

Q37373261-E2EDBD56-F660-4D78-83DA-DFAABB5B8F0B

P698

Q37373261-EF850562-29E5-429B-9C39-163300BF2A77

P921

Q37373261-ED72C198-B46C-4A86-A7A5-67C00B220220

P932

Q37373261-423F3F95-05C8-4FB9-BEDE-2DDAC670E51C

P356

WJG.V22.I40.8910

P1433

World Journal of Gastroenterology

P1476

Polymorphisms and resistance m ...... ean hepatitis C virus database

@en

P2093

Ana Beatriz Gorini da Veiga

http://www.w3.org/2001/XMLSchema#string

Angelo Alves de Mattos

http://www.w3.org/2001/XMLSchema#string

Charles Wood

http://www.w3.org/2001/XMLSchema#string

Dimas Alexandre Kliemann

http://www.w3.org/2001/XMLSchema#string

P2860

MEGA6: Molecular Evolutionary Genetics Analysis version 6.0

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

A new evolutionary model for hepatitis C virus chronic infection.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan.

P304

8910-8917

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V22.I40.8910

http://www.w3.org/2001/XMLSchema#string

P407

P433

40

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Cristiane Valle Tovo

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27833382

http://www.w3.org/2001/XMLSchema#string

P921

P932

5083796

http://www.w3.org/2001/XMLSchema#string